(Q33503354)

English

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

revascularization

1 reference

based on heuristic

inferred from title

thrombocytopenia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

8

object named as

R M Califf

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

S D Berkowitz

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

D C Sane

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

K N Sigmon

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

J H Shavender

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

R A Harrington

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

J E Tcheng

6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

1 August 1998

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Journal of the American College of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

311-319

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombin activity induced by balloon angioplasty of the coronary artery in Macaca fascicularis (cynomolgus monkey)

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Autoimmune thrombocytopenia: anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2898%2900252-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0735-1097(98)00252-6

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33503354&oldid=2105045125"